Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.

Buggisch P, Wursthorn K, Stoehr A, Atanasov PK, Supiot R, Lee J, Ting J, Petersen J.

PLoS One. 2019 Apr 4;14(4):e0214795. doi: 10.1371/journal.pone.0214795. eCollection 2019.

2.

Discontinuation of oral antivirals in chronic hepatitis B: A systematic review.

Papatheodoridis G, Vlachogiannakos I, Cholongitas E, Wursthorn K, Thomadakis C, Touloumi G, Petersen J.

Hepatology. 2016 May;63(5):1481-92. doi: 10.1002/hep.28438. Epub 2016 Mar 4. Review.

PMID:
27100145
3.

Variability in long-term hepatitis B virus dynamics under antiviral therapy.

Murray JM, Stancevic O, Lütgehetmann M, Wursthorn K, Petersen J, Dandri M.

J Theor Biol. 2016 Feb 21;391:74-80. doi: 10.1016/j.jtbi.2015.12.005. Epub 2015 Dec 23.

PMID:
26723531
4.

Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy.

Marcellin P, Wursthorn K, Wedemeyer H, Chuang WL, Lau G, Avila C, Peng CY, Gane E, Lim SG, Fainboim H, Foster GR, Safadi R, Rizzetto M, Manns M, Bao W, Trylesinski A, Naoumov N.

J Hepatol. 2015 Jan;62(1):41-7. doi: 10.1016/j.jhep.2014.08.021. Epub 2014 Aug 23.

PMID:
25152207
5.

Rapid hepatitis B and hepatitis Delta virus RNA quantification from small-sized liver tissue samples.

Taranta A, Rogalska-Taranta M, Gutierrez R, Manns MP, Bock M, Wursthorn K.

J Clin Virol. 2014 Oct;61(2):286-8. doi: 10.1016/j.jcv.2014.07.016. Epub 2014 Aug 2. No abstract available.

PMID:
25151628
6.

[Management of late presenters with opportunistic diseases: when and how to start ART].

Stoehr A, Lorenzen T, Wursthorn K.

MMW Fortschr Med. 2014 Jun 12;156 Suppl 1:33-6. Review. German. No abstract available.

PMID:
25026855
7.

Hepatitis B virus DNA quantification with the three-in-one (3io) method allows accurate single-step differentiation of total HBV DNA and cccDNA in biopsy-size liver samples.

Taranta A, Tien Sy B, Zacher BJ, Rogalska-Taranta M, Manns MP, Bock CT, Wursthorn K.

J Clin Virol. 2014 Aug;60(4):354-60. doi: 10.1016/j.jcv.2014.04.015. Epub 2014 May 2.

PMID:
24890819
8.

Increased HEV seroprevalence in patients with autoimmune hepatitis.

Pischke S, Gisa A, Suneetha PV, Wiegand SB, Taubert R, Schlue J, Wursthorn K, Bantel H, Raupach R, Bremer B, Zacher BJ, Schmidt RE, Manns MP, Rifai K, Witte T, Wedemeyer H.

PLoS One. 2014 Jan 21;9(1):e85330. doi: 10.1371/journal.pone.0085330. eCollection 2014.

9.

Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients.

Arendt E, Jaroszewicz J, Rockstroh J, Meyer-Olson D, Zacher BJ, Mederacke I, Manns MP, Wedemeyer H, Cornberg M, Wursthorn K.

Viral Immunol. 2012 Dec;25(6):442-7. doi: 10.1089/vim.2012.0036. Epub 2012 Nov 6.

PMID:
23131018
10.

In vivo selection of transplanted hepatocytes by pharmacological inhibition of fumarylacetoacetate hydrolase in wild-type mice.

Paulk NK, Wursthorn K, Haft A, Pelz C, Clarke G, Newell AH, Olson SB, Harding CO, Finegold MJ, Bateman RL, Witte JF, McClard R, Grompe M.

Mol Ther. 2012 Oct;20(10):1981-7. doi: 10.1038/mt.2012.154. Epub 2012 Aug 7.

11.

Ectopic expression of murine CD47 minimizes macrophage rejection of human hepatocyte xenografts in immunodeficient mice.

Waern JM, Yuan Q, Rüdrich U, Becker PD, Schulze K, Strick-Marchand H, Huntington ND, Zacher BJ, Wursthorn K, DiSanto JP, Guzman CA, Manns MP, Ott M, Bock M.

Hepatology. 2012 Oct;56(4):1479-88. doi: 10.1002/hep.25816.

PMID:
22535707
12.

Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues.

Jaroszewicz J, Ho H, Markova A, Deterding K, Wursthorn K, Schulz S, Bock CT, Tillmann HL, Manns MP, Wedemeyer H, Cornberg M.

Antivir Ther. 2011;16(6):915-24. doi: 10.3851/IMP1866.

PMID:
21900724
13.

Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay.

Zacher BJ, Moriconi F, Bowden S, Hammond R, Louisirirotchanakul S, Phisalprapa P, Tanwandee T, Wursthorn K, Brunetto MR, Wedemeyer H, Bonino F.

Clin Vaccine Immunol. 2011 Nov;18(11):1943-50. doi: 10.1128/CVI.05122-11. Epub 2011 Aug 31.

14.

Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation.

Mederacke I, Filmann N, Yurdaydin C, Bremer B, Puls F, Zacher BJ, Heidrich B, Tillmann HL, Rosenau J, Bock CT, Savas B, Helfritz F, Lehner F, Strassburg CP, Klempnauer J, Wursthorn K, Lehmann U, Manns MP, Herrmann E, Wedemeyer H.

J Hepatol. 2012 Jan;56(1):115-22. doi: 10.1016/j.jhep.2011.06.016. Epub 2011 Jul 14.

PMID:
21762665
15.

Republished paper: Managing HBV in patients with impaired immunity.

Wursthorn K, Wedemeyer H, Manns MP.

Postgrad Med J. 2011 Mar;87(1025):223-38. doi: 10.1136/pgmj.2009.195834rep.

PMID:
21357572
16.

Different kinetics of HBV and HCV during haemodialysis and absence of seronegative viral hepatitis in patients with end-stage renal disease.

Mederacke I, Meier M, Lüth JB, Schmidt-Gürtler H, Raupach R, Horn-Wichmann R, Wursthorn K, Potthoff A, Colucci G, Manns MP, Wedemeyer H, Tillmann HL.

Nephrol Dial Transplant. 2011 Aug;26(8):2648-56. doi: 10.1093/ndt/gfq757. Epub 2011 Jan 27.

PMID:
21273235
17.

Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum.

Wursthorn K, Jaroszewicz J, Zacher BJ, Darnedde M, Raupach R, Mederacke I, Cornberg M, Manns MP, Wedemeyer H.

J Clin Virol. 2011 Apr;50(4):292-6. doi: 10.1016/j.jcv.2010.12.008. Epub 2011 Jan 26.

PMID:
21273117
18.

Development of a protocol for the quantitative determination of HBeAg using the Elecsys® HBeAg immunoassay.

Wursthorn K, Zacher BJ, Jaroszewicz J, Darnedde M, Manns M, Wedemeyer H.

J Viral Hepat. 2011 Jul;18(7):e179-83. doi: 10.1111/j.1365-2893.2010.01419.x. Epub 2010 Dec 30.

PMID:
21199189
19.

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.

Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, Manns MP, Wedemeyer H, Naoumov NV.

Hepatology. 2010 Nov;52(5):1611-20. doi: 10.1002/hep.23905.

PMID:
20931556
20.

Managing HBV in patients with impaired immunity.

Wursthorn K, Wedemeyer H, Manns MP.

Gut. 2010 Oct;59(10):1430-45. doi: 10.1136/gut.2009.195834. Epub 2010 Jun 4. Review.

PMID:
20525968
21.

Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics.

Mederacke I, Bremer B, Heidrich B, Kirschner J, Deterding K, Bock T, Wursthorn K, Manns MP, Wedemeyer H.

J Clin Microbiol. 2010 Jun;48(6):2022-9. doi: 10.1128/JCM.00084-10. Epub 2010 Mar 29.

22.

Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.

Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, Flisiak R, Bock CT, Manns MP, Wedemeyer H, Cornberg M.

J Hepatol. 2010 Apr;52(4):514-22. doi: 10.1016/j.jhep.2010.01.014. Epub 2010 Feb 13.

PMID:
20207438
23.

[Interferon-alfa induced reactivation of sarcoidosis in a patient with chronic hepatitis C].

Mederacke I, Wursthorn K, Ho H, Manns MP, Wedemeyer H.

Internist (Berl). 2010 Apr;51(4):522-7. doi: 10.1007/s00108-009-2543-3. German.

PMID:
20186385
24.

Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo.

Paulk NK, Wursthorn K, Wang Z, Finegold MJ, Kay MA, Grompe M.

Hepatology. 2010 Apr;51(4):1200-8. doi: 10.1002/hep.23481.

25.

Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab.

Stange MA, Tutarel O, Pischke S, Schneider A, Strassburg CP, Becker T, Barg-Hock H, Bastürk M, Wursthorn K, Cornberg M, Ott M, Greten TF, Manns MP, Wedemeyer H.

Z Gastroenterol. 2010 Feb;48(2):258-63. doi: 10.1055/s-0028-1109782. Epub 2010 Feb 2.

PMID:
20127601
26.

Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay.

Mederacke I, Wedemeyer H, Ciesek S, Steinmann E, Raupach R, Wursthorn K, Manns MP, Tillmann HL.

J Clin Virol. 2009 Nov;46(3):210-5. doi: 10.1016/j.jcv.2009.08.014. Epub 2009 Sep 17.

PMID:
19766055
27.

Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection.

Mederacke I, Wursthorn K, Kirschner J, Rifai K, Manns MP, Wedemeyer H, Bahr MJ.

Liver Int. 2009 Nov;29(10):1500-6. doi: 10.1111/j.1478-3231.2009.02100.x. Epub 2009 Sep 3.

PMID:
19732330
28.

Natural history: the importance of viral load, liver damage and HCC.

Wursthorn K, Manns MP, Wedemeyer H.

Best Pract Res Clin Gastroenterol. 2008;22(6):1063-79. doi: 10.1016/j.bpg.2008.11.006. Review.

PMID:
19187867
29.

Tracking of human cells in mice.

Schormann W, Hammersen FJ, Brulport M, Hermes M, Bauer A, Rudolph C, Schug M, Lehmann T, Nussler A, Ungefroren H, Hutchinson J, Fändrich F, Petersen J, Wursthorn K, Burda MR, Brüstle O, Krishnamurthi K, von Mach M, Hengstler JG.

Histochem Cell Biol. 2008 Aug;130(2):329-38. doi: 10.1007/s00418-008-0428-5. Epub 2008 Apr 19.

PMID:
18425526
30.

Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial.

Kronenberger B, Berg T, Herrmann E, Hinrichsen H, Gerlach T, Buggisch P, Spengler U, Goeser T, Nasser S, Wursthorn K, Pape GR, Hopf U, Zeuzem S.

Eur J Gastroenterol Hepatol. 2007 Aug;19(8):639-46.

PMID:
17625432
31.

Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV.

Wursthorn K, Buggisch P, Lutgehetmann M, Zollner B, Petersen J.

Antivir Ther. 2006;11(5):647-52.

PMID:
16964835
32.

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.

Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J.

Hepatology. 2006 Sep;44(3):675-84.

PMID:
16941693
33.
34.

Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes.

Dandri M, Burda MR, Zuckerman DM, Wursthorn K, Matschl U, Pollok JM, Rogiers X, Gocht A, Köck J, Blum HE, von Weizsäcker F, Petersen J.

J Hepatol. 2005 Jan;42(1):54-60.

PMID:
15629507
35.

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE 4th, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F.

Gastroenterology. 2004 Jun;126(7):1750-8.

PMID:
15188170
36.

First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C.

Reiser M, Buggisch P, Grossmann J, Koop K, Wursthorn K, Schmiegel W.

Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1299-304.

PMID:
14624153
37.

Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.

Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, Herrmann E, Spengler U, Goeser T, Nasser S, Wursthorn K, Pape GR, Hopf U, Zeuzem S.

Hepatology. 2003 Jun;37(6):1359-67.

PMID:
12774015
38.

Expression, purification, crystallization and preliminary X-ray analysis of rat ecto-ADP-ribosyltransferase 2 (ART2.2).

Mueller-Dieckmann C, Scheuermann T, Wursthorn K, Schröder J, Haag F, Schulz GE, Koch-Nolte F.

Acta Crystallogr D Biol Crystallogr. 2002 Jul;58(Pt 7):1211-3. Epub 2002 Jun 20.

PMID:
12077446
39.

Supplemental Content

Loading ...
Support Center